Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136384690> ?p ?o ?g. }
- W3136384690 endingPage "582" @default.
- W3136384690 startingPage "568" @default.
- W3136384690 abstract "Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by SMPD3, catalyzes the breakdown of sphingomyelin to produce the anti-oncometabolite ceramide. We found that this enzyme was often downregulated in human metastatic melanoma, likely contributing to immune escape. Overexpression of nSMase2 in mouse melanoma reduced tumor growth in syngeneic wild-type but not CD8-deficient mice. In wild-type mice, nSMase2-overexpressing tumors showed accumulation of both ceramide and CD8+ tumor-infiltrating lymphocytes, and this was associated with increased level of transcripts encoding IFNγ and CXCL9. Overexpressing the catalytically inactive nSMase2 failed to alter tumor growth, indicating that the deleterious effect nSMase2 has on melanoma growth depends on its enzymatic activity. In vitro, small extracellular vesicles from melanoma cells overexpressing wild-type nSMase2 augmented the expression of IL12, CXCL9, and CCL19 by bone marrow-derived dendritic cells, suggesting that melanoma nSMase2 triggers T helper 1 (Th1) polarization in the earliest stages of the immune response. Most importantly, overexpression of wild-type nSMase2 increased anti-PD-1 efficacy in murine models of melanoma and breast cancer, and this was associated with an enhanced Th1 response. Therefore, increasing SMPD3 expression in melanoma may serve as an original therapeutic strategy to potentiate Th1 polarization and CD8+ T-cell-dependent immune responses and overcome resistance to anti-PD-1." @default.
- W3136384690 created "2021-03-29" @default.
- W3136384690 creator A5000810765 @default.
- W3136384690 creator A5000843839 @default.
- W3136384690 creator A5002724974 @default.
- W3136384690 creator A5003424696 @default.
- W3136384690 creator A5007710971 @default.
- W3136384690 creator A5008268675 @default.
- W3136384690 creator A5008647126 @default.
- W3136384690 creator A5020029085 @default.
- W3136384690 creator A5022584885 @default.
- W3136384690 creator A5027985283 @default.
- W3136384690 creator A5028105150 @default.
- W3136384690 creator A5032996061 @default.
- W3136384690 creator A5033690333 @default.
- W3136384690 creator A5033900987 @default.
- W3136384690 creator A5033995803 @default.
- W3136384690 creator A5038403474 @default.
- W3136384690 creator A5039224442 @default.
- W3136384690 creator A5044542630 @default.
- W3136384690 creator A5052434973 @default.
- W3136384690 creator A5064811728 @default.
- W3136384690 creator A5066060316 @default.
- W3136384690 creator A5067794998 @default.
- W3136384690 creator A5073545182 @default.
- W3136384690 creator A5078851435 @default.
- W3136384690 creator A5079449135 @default.
- W3136384690 creator A5081053692 @default.
- W3136384690 creator A5082532521 @default.
- W3136384690 creator A5085268074 @default.
- W3136384690 creator A5090422329 @default.
- W3136384690 date "2021-03-16" @default.
- W3136384690 modified "2023-10-14" @default.
- W3136384690 title "Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy" @default.
- W3136384690 cites W1534320734 @default.
- W3136384690 cites W1566441785 @default.
- W3136384690 cites W1594494382 @default.
- W3136384690 cites W1950829641 @default.
- W3136384690 cites W1966452335 @default.
- W3136384690 cites W1966929992 @default.
- W3136384690 cites W1976722625 @default.
- W3136384690 cites W1993093223 @default.
- W3136384690 cites W2001160697 @default.
- W3136384690 cites W2006659499 @default.
- W3136384690 cites W2006985918 @default.
- W3136384690 cites W2012394768 @default.
- W3136384690 cites W2033421880 @default.
- W3136384690 cites W2035000040 @default.
- W3136384690 cites W2050689467 @default.
- W3136384690 cites W2057113047 @default.
- W3136384690 cites W2068683449 @default.
- W3136384690 cites W2070005836 @default.
- W3136384690 cites W2075251669 @default.
- W3136384690 cites W2078702640 @default.
- W3136384690 cites W2080902832 @default.
- W3136384690 cites W2086162615 @default.
- W3136384690 cites W2097198003 @default.
- W3136384690 cites W2105650855 @default.
- W3136384690 cites W2111796864 @default.
- W3136384690 cites W2114843025 @default.
- W3136384690 cites W2115538252 @default.
- W3136384690 cites W2119764013 @default.
- W3136384690 cites W2119812304 @default.
- W3136384690 cites W2130226531 @default.
- W3136384690 cites W2130398615 @default.
- W3136384690 cites W2130410032 @default.
- W3136384690 cites W2133717967 @default.
- W3136384690 cites W2134471382 @default.
- W3136384690 cites W2141003137 @default.
- W3136384690 cites W2146073081 @default.
- W3136384690 cites W2149441684 @default.
- W3136384690 cites W2155850284 @default.
- W3136384690 cites W2156164763 @default.
- W3136384690 cites W2166662937 @default.
- W3136384690 cites W2255975777 @default.
- W3136384690 cites W2417761579 @default.
- W3136384690 cites W2525871238 @default.
- W3136384690 cites W2554320328 @default.
- W3136384690 cites W2572174216 @default.
- W3136384690 cites W2656748229 @default.
- W3136384690 cites W2769383666 @default.
- W3136384690 cites W2779658193 @default.
- W3136384690 cites W2786818729 @default.
- W3136384690 cites W2796153844 @default.
- W3136384690 cites W2887249435 @default.
- W3136384690 cites W2903060444 @default.
- W3136384690 cites W2911800642 @default.
- W3136384690 cites W2934922729 @default.
- W3136384690 cites W2943529297 @default.
- W3136384690 cites W3001874526 @default.
- W3136384690 cites W3091256843 @default.
- W3136384690 cites W4230040411 @default.
- W3136384690 doi "https://doi.org/10.1158/2326-6066.cir-20-0342" @default.
- W3136384690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33727246" @default.
- W3136384690 hasPublicationYear "2021" @default.
- W3136384690 type Work @default.
- W3136384690 sameAs 3136384690 @default.
- W3136384690 citedByCount "27" @default.